



## Clinical trial results:

### An Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) in First Relapse

#### Summary

EudraCT number	2015-001173-41
Trial protocol	Outside EU/EEA
Global end of trial date	26 April 2011

#### Results information

Result version number	v1 (current)
This version publication date	23 May 2016
First version publication date	05 August 2015

#### Trial information

##### Trial identification

Sponsor protocol code	CLO08808
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00991133
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Genzyme Corporation
Sponsor organisation address	500 Kendall Street, Cambridge, MA, United States, 02142
Public contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	26 April 2011
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 April 2011
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The primary objective was to evaluate the safety of 1 cycle of the 5-drug regimen in pediatric subjects with acute lymphoblastic leukemia (ALL) who were in first bone marrow relapse.

Protection of trial subjects:

Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency.

Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

The study was conducted by investigators experienced in the treatment of pediatric subjects. The parent(s) or guardian(s) as well as the children were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time. In addition to the consent form for the parent(s)/guardian(s), an assent form in child-appropriate language was provided and explained to the child. Repeated invasive procedures were minimized. The number of blood samples as well as the amount of blood drawn were adjusted according to age and weight. A topical anesthesia may have been used to minimize distress and discomfort.

---

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 January 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	United States: 8
Worldwide total number of subjects	8
EEA total number of subjects	0

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	4
Adolescents (12-17 years)	2
Adults (18-64 years)	2
From 65 to 84 years	0
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 6 centers in United States of America. A total of 8 subjects were screened between 08 January 2010 and 10 November 2010.

### Pre-assignment

Screening details:

All subjects were treated.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Overall Population
-----------	--------------------

Arm description:

Subjects received 5 drug regimen: clofarabine, etoposide, cyclophosphamide (Days 1-5), PEG-asparaginase (Day 15) and vincristine (Days 15-22) in each 28 day cycle for maximum 2 cycles. Subjects who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and subjects who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.

Arm type	Experimental
Investigational medicinal product name	Clofarabine
Investigational medicinal product code	
Other name	Clolar
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

40 mg/m<sup>2</sup>

Investigational medicinal product name	Etoposide
Investigational medicinal product code	
Other name	VP-16
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

100 mg/m<sup>2</sup>

Investigational medicinal product name	Cyclophosphamide
Investigational medicinal product code	
Other name	Cytosan
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

440 mg/m<sup>2</sup>

Investigational medicinal product name	PEG-asparaginase
Investigational medicinal product code	
Other name	PEGAspar-aginase
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

2500 IU/m<sup>2</sup>

Investigational medicinal product name	Vincristine
Investigational medicinal product code	
Other name	Oncovin
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

1.5 mg/m<sup>2</sup> (maximum dose 2 mg)

<b>Number of subjects in period 1</b>	Overall Population
Started	8
Completed	0
Not completed	8
Consent withdrawn by subject	2
Sponsor or Investigator decision	2
Adverse event or treatment toxicity	2
Subject scheduled to receive transplant or therapy	2

## Baseline characteristics

### Reporting groups

Reporting group title	Overall Population
-----------------------	--------------------

Reporting group description:

Subjects received 5 drug regimen: clofarabine, etoposide, cyclophosphamide (Days 1-5), PEG-asparaginase (Day 15) and vincristine (Days 15-22) in each 28 day cycle for maximum 2 cycles. Subjects who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and subjects who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.

Reporting group values	Overall Population	Total	
Number of subjects	8	8	
Age categorical			
Units: Subjects			
Children (2-11 years)	4	4	
Adolescents (12-17 years)	2	2	
Adults (18-64 years)	2	2	
Gender categorical			
Units: Subjects			
Female	6	6	
Male	2	2	

## End points

### End points reporting groups

Reporting group title	Overall Population
Reporting group description: Subjects received 5 drug regimen: clofarabine, etoposide, cyclophosphamide (Days 1-5), PEG-asparaginase (Day 15) and vincristine (Days 15-22) in each 28 day cycle for maximum 2 cycles. Subjects who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and subjects who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.	

### Primary: Number of Subjects Who Experienced Dose Limiting Toxicity

End point title	Number of Subjects Who Experienced Dose Limiting Toxicity <sup>[1]</sup>
End point description: All enrolled subjects were analysed.	
End point type	Primary
End point timeframe: Cycle 1	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis was performed as the analysis was descriptive.	

End point values	Overall Population			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: subjects	4			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Complete Remission (CR)

End point title	Number of Subjects with Complete Remission (CR)
End point description: All enrolled subjects were analysed.	
End point type	Secondary
End point timeframe: Cycle 1	

<b>End point values</b>	Overall Population			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: subjects	3			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Remission and Duration of Remission

End point title	Time to Remission and Duration of Remission
End point description:	Time to remission was defined as time from date of first administration of study drugs until date of first objective documentation of CR. Analysis was performed on subjects who achieved CR.
End point type	Secondary
End point timeframe:	Baseline up to first objective documentation of CR

<b>End point values</b>	Overall Population			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[2]</sup>			
Units: weeks				
number (not applicable)				

Notes:

[2] - No summary analyses performed. No efficacy conclusion could be drawn due to small number of subjects

### Statistical analyses

No statistical analyses for this end point

### Secondary: Disease-Free Survival (DFS)

End point title	Disease-Free Survival (DFS)
End point description:	DFS was defined as time from date of first objective documentation of CR until the earlier of date of objective documentation of disease relapse or date of death due to any cause, regardless of intervening alternative anti-leukemic therapy ( including hematopoietic stem cell transplant). Analysis was performed on subjects who achieved CR.
End point type	Secondary
End point timeframe:	First objective documentation of CR until the earlier of date of objective documentation of disease relapse or date of death due to any cause

<b>End point values</b>	Overall Population			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[3]</sup>			
Units: weeks				
number (not applicable)				

Notes:

[3] - No summary analyses performed. No efficacy conclusion could be drawn due to small number of subjects

### Statistical analyses

No statistical analyses for this end point

### Secondary: Event-Free Survival (EFS)

End point title	Event-Free Survival (EFS)
-----------------	---------------------------

End point description:

EFS was defined as time from date of first administration of study drugs until the earliest date of death due to any cause, occurrence of a treatment-related secondary neoplasm, first response assessment confirming relapse (for subjects who achieved CR); or final response assessment that failed to confirm response (CR). All enrolled subjects were analysed

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to death due to any cause, treatment-related secondary neoplasm, first response assessment confirming relapse (for subjects who achieved CR); or final response assessment that failed to confirm response, whichever occurred first

<b>End point values</b>	Overall Population			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[4]</sup>			
Units: weeks				
number (not applicable)				

Notes:

[4] - No summary analyses performed. No efficacy conclusion could be drawn due to small number of subjects

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects who achieved 4-Months EFS

End point title	Number of subjects who achieved 4-Months EFS
-----------------	--

End point description:

Four-month events free survival: Duration of EFS was at least 4 months post initial administration of the 5-drug regimen. All enrolled subjects were analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to 4 months

<b>End point values</b>	Overall Population			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: subjects	6			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival

End point title	Overall Survival
End point description: Time from date of first administration of study drugs until date of death due to any cause. All enrolled subjects were analysed.	
End point type	Secondary
End point timeframe: Baseline up to death due to any cause	

<b>End point values</b>	Overall Population			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[5]</sup>			
Units: weeks				
number (not applicable)				

Notes:

[5] - No summary analyses performed. No efficacy conclusion could be drawn due to small number of subjects

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (cycle 1) regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

Reported adverse events and deaths are treatment-emergent that is AEs that developed/worsened during the 'on treatment period' (from the first dose study drugs up to last dose of study drug).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	13.1

### Reporting groups

Reporting group title	Overall Population
-----------------------	--------------------

Reporting group description:

Subjects received 5 drug regimen: clofarabine, etoposide, cyclophosphamide (Days 1-5), PEG-asparaginase (Day 15) and vincristine (Days 15-22) in each 28 day cycle for maximum 2 cycles. Subjects who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and subjects who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.

<b>Serious adverse events</b>	Overall Population		
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 8 (50.00%)		
number of deaths (all causes)	4		
number of deaths resulting from adverse events			
Investigations			
Blood Bilirubin Increased			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Lipase Increased			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Thrombosis			

subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac Failure Congestive			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Leukoencephalopathy			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Bone Marrow Failure			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Febrile Neutropenia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute Respiratory Distress Syndrome			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			

subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Infections and infestations</b>			
Fungal Skin Infection			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Enterococcal Bacteraemia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia Respiratory Syncytial Viral			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia Fungal			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	1 / 1		
<b>Metabolism and nutrition disorders</b>			
Hypernatraemia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Overall Population		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 8 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Tumour Pain subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Vascular disorders			
Hypertension subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 3		
Haematoma subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Thrombosis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Poor Peripheral Circulation subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Hypotension subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 3		
General disorders and administration site conditions			
Generalised Oedema subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2		
Chills subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 3		
Chest Pain subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2		
Fatigue subjects affected / exposed occurrences (all)	4 / 8 (50.00%) 5		
Mucosal Inflammation subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Pyrexia			

subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 4		
Immune system disorders Drug Hypersensitivity subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Reproductive system and breast disorders Ovarian Cyst subjects affected / exposed occurrences (all)  Vulvovaginal Pain subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1  1 / 8 (12.50%) 1		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Dyspnoea subjects affected / exposed occurrences (all)  Haemoptysis subjects affected / exposed occurrences (all)  Pleural Effusion subjects affected / exposed occurrences (all)  Wheezing subjects affected / exposed occurrences (all)  Tachypnoea subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2  1 / 8 (12.50%) 1  1 / 8 (12.50%) 1  1 / 8 (12.50%) 1  1 / 8 (12.50%) 1  1 / 8 (12.50%) 1		
Psychiatric disorders Agitation subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		

Anxiety			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Confusional State			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Disorientation			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Depression			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	3		
Aspartate Aminotransferase Increased			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Blood Creatinine Increased			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Blood Bilirubin Increased			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Blood Amylase Increased			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	3		
Blood Triglycerides Increased			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Enterococcus Test Positive			

subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Gallop Rhythm Present subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Mycobacterium Test Positive subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Specific Gravity Urine Abnormal subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Lipase Increased subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 3		
Weight Increased subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Injury, poisoning and procedural complications			
Allergic Transfusion Reaction subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Transfusion Reaction subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Cardiac disorders			
Tachycardia subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Pericardial Haemorrhage subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	4 / 8 (50.00%) 4		
Dizziness			

subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Tremor subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Neuropathy Peripheral subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	7 / 8 (87.50%) 17		
Leukopenia subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 4		
Febrile Neutropenia subjects affected / exposed occurrences (all)	5 / 8 (62.50%) 5		
Lymphopenia subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Pancytopenia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Neutropenia subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 4		
Splenic Necrosis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Thrombocytopenia subjects affected / exposed occurrences (all)	6 / 8 (75.00%) 9		
Ear and labyrinth disorders Ear Pain			

subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Eye disorders			
Ocular Hyperaemia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Diplopia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Vitreous Floaters subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Photophobia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Gastrointestinal disorders			
Abdominal Pain subjects affected / exposed occurrences (all)	6 / 8 (75.00%) 7		
Chapped Lips subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Anal Erosion subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Abdominal Pain Upper subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Constipation subjects affected / exposed occurrences (all)	4 / 8 (50.00%) 4		
Diarrhoea subjects affected / exposed occurrences (all)	5 / 8 (62.50%) 5		
Gastrointestinal Haemorrhage			

subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Nausea subjects affected / exposed occurrences (all)	8 / 8 (100.00%) 10		
Pancreatitis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Gingival Bleeding subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Rectal Fissure subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Proctalgia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Vomiting subjects affected / exposed occurrences (all)	7 / 8 (87.50%) 10		
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 3		
Hepatomegaly subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Skin and subcutaneous tissue disorders Drug Eruption subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Alopecia			

subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 3		
Blister subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 7		
Palmar Erythema subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Dry Skin subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Night Sweats subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Pruritus subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Pruritus Generalised subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Rash Generalised subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2		
Purpura subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Rash subjects affected / exposed occurrences (all)	4 / 8 (50.00%) 6		
Skin Exfoliation subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Renal and urinary disorders Glycosuria subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		

Haematuria subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Dysuria subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Haemoglobinuria subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Pollakiuria subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Proteinuria subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 4		
Musculoskeletal and connective tissue disorders			
Back Pain subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 3		
Arthralgia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Musculoskeletal Pain subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 3		
Pain In Extremity subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Infections and infestations			
Bk Virus Infection subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Endocarditis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Cystitis			

subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Sinusitis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Psoas Abscess subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Urinary Tract Infection Bacterial subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Metabolism and nutrition disorders			
Hyperamylasaemia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2		
Decreased Appetite subjects affected / exposed occurrences (all)	7 / 8 (87.50%) 9		
Hyperuricaemia subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		
Hyperglycaemia subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 5		
Hypocalcaemia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1		
Hypoalbuminaemia subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 5		
Hypomagnesaemia subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2		

Hypokalaemia			
subjects affected / exposed	4 / 8 (50.00%)		
occurrences (all)	5		
Hyponatraemia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Hypophosphataemia			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 July 2010	Seven subjects were enrolled under the original protocol, and 1 subject was enrolled under the amended protocol.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported